Supernus Pharmaceuticals, Inc. (SUPN)

Environment story

Supernus discloses no Scope 1, Scope 2, or Scope 3 emissions data in the 10-K filing. No net-zero target or climate commitments are disclosed. No environmental controversies, resource depletion incidents, toxic-waste litigation, or water-stress events are mentioned in the risk factors or MD&A. The company operates as a pharmaceutical manufacturer relying heavily on contract manufacturers and outsourced supply chains; product manufacturing emissions (particularly from clinical-trial and commercial supply chains) are not quantified. No renewable-energy investments or decarbonization infrastructure are disclosed. The absence of environmental disclosure itself is penalized under the deterministic rubric.

Social story

Supernus does not disclose CEO-to-median-worker pay ratios, workforce turnover rates, diversity metrics (gender/race/ethnicity), union standing, or labor relations status in the 10-K. No documented union-suppression activities, strikes, or NLRB complaints are mentioned. No executive or board diversity percentages are provided. The company discloses reliance on third-party contract research organizations (CROs) and contract manufacturers (CMOs) but does not detail supply-chain human-rights audits, conflict-minerals policies, forced-labor assessments, or living-wage commitments. No formal diversity, equity, and inclusion (DEI) programs, supplier-diversity initiatives, or civil-rights audits are mentioned. The lack of substantive labor and social disclosures results in a moderate deduction.

Governance story

Supernus does not disclose board composition, independence percentages, or share-class structure in the provided 10-K excerpts. No dual-class voting structure is mentioned; no supermajority founder control is identified. No lobbying expenditures, political action committee (PAC) contributions, or trade-association memberships are disclosed in the filing. The 10-K does not report active antitrust, consumer-safety, or financial-fraud regulatory proceedings. The company faces substantial product-liability litigation risks and patent-infringement disputes mentioned in risk factors, but these are standard for pharmaceutical firms and not characterized as ongoing regulatory enforcement actions. The company's reliance on FDA approval processes and post-approval commitments creates regulatory compliance risk, but no specific consent decrees or settlement orders are referenced in the excerpt.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Supernus Pharmaceuticals, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Supernus Pharmaceuticals, Inc. in the app for interactive charts and portfolio building.

More in Healthcare